Literature DB >> 14512571

Immunogenicity and pathogenicity of chimeric infectious DNA clones of pathogenic porcine circovirus type 2 (PCV2) and nonpathogenic PCV1 in weanling pigs.

M Fenaux1, T Opriessnig, P G Halbur, X J Meng.   

Abstract

Porcine circovirus type 2 (PCV2) is the primary causative agent of postweaning multisystemic wasting syndrome (PMWS), whereas the ubiquitous porcine circovirus type 1 (PCV1) is nonpathogenic for pigs. We report here the construction and characterization of two chimeric infectious DNA clones of PCV1 and PCV2. The chimeric PCV1-2 clone contains the PCV2 capsid gene cloned in the backbone of the nonpathogenic PCV1 genome. A reciprocal chimeric PCV2-1 DNA clone was also constructed by replacing the PCV2 capsid gene with that of PCV1 in the backbone of the PCV2 genome. The PCV1, PCV2, and chimeric PCV1-2 and PCV2-1 DNA clones were all shown to be infectious in PK-15 cells, and their growth characteristics in vitro were determined and compared. To evaluate the immunogenicity and pathogenicity of the chimeric infectious DNA clones, 40 specific-pathogen-free (SPF) pigs were randomly assigned into five groups of eight pigs each. Group 1 pigs received phosphate-buffered saline as the negative control. Group 2 pigs were each injected in the superficial inguinal lymph nodes with 200 micro g of the PCV1 infectious DNA clone. Group 3 pigs were each similarly injected with 200 micro g of the PCV2 infectious DNA clone, group 4 pigs were each injected with 200 micro g of the chimeric PCV1-2 infectious DNA clone, and group 5 pigs were each injected with 200 micro g of the reciprocal chimeric PCV2-1 infectious DNA clone. As expected, seroconversion to antibodies to the PCV2 capsid antigen was detected in group 3 and group 4 pigs. Group 2 and 5 pigs all seroconverted to PCV1 antibody. Gross and microscopic lesions in various tissues of animals inoculated with the PCV2 infectious DNA clone were significantly more severe than those found in pigs inoculated with PCV1, chimeric PCV1-2, and reciprocal chimeric PCV2-1 infectious DNA clones. These data indicated that the chimeric PCV1-2 virus with the immunogenic ORF2 capsid gene of pathogenic PCV2 cloned into the nonpathogenic PCV1 genomic backbone induces a specific antibody response to the pathogenic PCV2 capsid antigen but is attenuated in pigs. Future studies are warranted to evaluate the usefulness of the chimeric PCV1-2 infectious DNA clone as a genetically engineered live-attenuated vaccine against PCV2 infection and PMWS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512571      PMCID: PMC224998          DOI: 10.1128/jvi.77.20.11232-11243.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Production, preliminary characterisation and applications of monoclonal antibodies to porcine circovirus.

Authors:  G M Allan; D P Mackie; J McNair; B M Adair; M S McNulty
Journal:  Vet Immunol Immunopathol       Date:  1994-11       Impact factor: 2.046

2.  Evidence of circovirus infection in British pigs.

Authors:  S Edwards; J J Sands
Journal:  Vet Rec       Date:  1994-06-25       Impact factor: 2.695

3.  Experimental inoculation of conventional pigs with tissue homogenates from pigs with post-weaning multisystemic wasting syndrome.

Authors:  M Balasch; J Segalés; C Rosell; M Domingo; A Mankertz; A Urniza; J Plana-Durán
Journal:  J Comp Pathol       Date:  1999-08       Impact factor: 1.311

4.  Presence of antibodies reacting with porcine circovirus in sera of humans, mice, and cattle.

Authors:  I Tischer; L Bode; J Apodaca; H Timm; D Peters; R Rasch; S Pociuli; E Gerike
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  In vivo transfection of bovine leukemia provirus into sheep.

Authors:  L Willems; D Portetelle; P Kerkhofs; G Chen; A Burny; M Mammerickx; R Kettmann
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

6.  Experimental inoculation of porcine circoviruses type 1 (PCV1) and type 2 (PCV2) in rabbits and mice.

Authors:  Josefina Quintana; Monica Balasch; Joaquim Segalés; Maria Calsamiglia; Gabriela M Rodríguez-Arrioja; Juan Plana-Durán; Mariano Domingo
Journal:  Vet Res       Date:  2002 May-Jun       Impact factor: 3.683

7.  Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus.

Authors:  P G Halbur; P S Paul; M L Frey; J Landgraf; K Eernisse; X J Meng; M A Lum; J J Andrews; J A Rathje
Journal:  Vet Pathol       Date:  1995-11       Impact factor: 2.221

8.  Pathogenesis of porcine circovirus; experimental infections of colostrum deprived piglets and examination of pig foetal material.

Authors:  G M Allan; F McNeilly; J P Cassidy; G A Reilly; B Adair; W A Ellis; M S McNulty
Journal:  Vet Microbiol       Date:  1995-04       Impact factor: 3.293

9.  Distribution of antibodies to porcine circovirus in swine populations of different breeding farms.

Authors:  I Tischer; L Bode; D Peters; S Pociuli; B Germann
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  Porcine circovirus antigens in PK-15 cell line (ATCC CCL-33) and evidence of antibodies to circovirus in Canadian pigs.

Authors:  G C Dulac; A Afshar
Journal:  Can J Vet Res       Date:  1989-10       Impact factor: 1.310

View more
  41 in total

1.  Epitope mapping of the major capsid protein of type 2 porcine circovirus (PCV2) by using chimeric PCV1 and PCV2.

Authors:  Porntippa Lekcharoensuk; Igor Morozov; Prem S Paul; Nattarat Thangthumniyom; Worawidh Wajjawalku; X J Meng
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

2.  Construction of a Lactobacillus plantarum Strain Expressing the Capsid Protein of Porcine Circovirus Type 2d (PCV2d) as an Oral Vaccine.

Authors:  Yi-Han Tseng; Cheng-Chu Hsieh; Tsun-Yung Kuo; Je-Ruei Liu; Ting-Yu Hsu; Shu-Chen Hsieh
Journal:  Indian J Microbiol       Date:  2019-10-23       Impact factor: 2.461

3.  Effects of porcine circovirus type 2 (PCV2) maternal antibodies on experimental infection of piglets with PCV2.

Authors:  N E McKeown; T Opriessnig; P Thomas; D K Guenette; F Elvinger; M Fenaux; P G Halbur; X J Meng
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

4.  Immunogenicity of empty capsids of porcine circovius type 2 produced in insect cells.

Authors:  H Fan; C Ju; T Tong; H Huang; J Lv; H Chen
Journal:  Vet Res Commun       Date:  2007-05       Impact factor: 2.459

5.  Phylogenetic and recombination analysis of genomic sequences of PCV2 isolated in Korea.

Authors:  Hye Kwon Kim; Yuzi Luo; Hyung Joon Moon; Seong Jun Park; Hyun Ok Keum; Semi Rho; Bong Kyun Park
Journal:  Virus Genes       Date:  2009-08-20       Impact factor: 2.332

6.  Rolling-circle replication of an animal circovirus genome in a theta-replicating bacterial plasmid in Escherichia coli.

Authors:  Andrew K Cheung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  The ORF3 protein of porcine circovirus type 2 is involved in viral pathogenesis in vivo.

Authors:  Jue Liu; Isabelle Chen; Qingyun Du; Huikheng Chua; Jimmy Kwang
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

8.  Replacement of the replication factors of porcine circovirus (PCV) type 2 with those of PCV type 1 greatly enhances viral replication in vitro.

Authors:  N M Beach; N M Juhan; L Cordoba; X J Meng
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

9.  Development and validation of an ELISA using a protein encoded by ORF2 antigenic domain of porcine circovirus type 2.

Authors:  Shi-Qi Sun; Hui-Chen Guo; De-Hui Sun; Shuang-Hui Yin; You-Jun Shang; Xue-Peng Cai; Xiang-Tao Liu
Journal:  Virol J       Date:  2010-10-19       Impact factor: 4.099

10.  Porcine circovirus type 2 (PCV2)-infection and re-inoculation with homologous or heterologous strains: virological, serological, pathological and clinical effects in growing pigs.

Authors:  Tanja Opriessnig; John R Prickett; Darin M Madson; Hui-Gang Shen; Nicole M Juhan; Roman R Pogranichniy; Xiang-Jin Meng; Patrick G Halbur
Journal:  Vet Res       Date:  2010-01-18       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.